Intensive Motivational Interviewing for Methamphetamine Dependence
NCT01071356 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 217
Last updated 2018-05-24
Summary
A Stage 2 randomized clinical trial (RCT) to test the efficacy of a 9-session model of motivational interviewing (MI) for methamphetamine (MA) dependence. Stage 1 pilot testing indicated the intervention could be easily learned and implemented with fidelity. The tailored treatment approach draws upon our previous conceptual papers on MI as well as our experience with a variety of MI protocols, including two Clinical Trials Network (CTN) studies of MI. An innovative feature of the "Higher Dose Motivational Enhancement Therapy" manual is that it comprehensively addresses the issues of clients who have achieved sustained sobriety as well as those still using substances. Thus, it is designed to facilitate treatment entry and engagement as well as maintenance of the gains made in treatment. MA dependent clients (N=220) were recruited from New Leaf outpatient treatment in Lafayette, California. Study participants were randomly assigned to 1) a single session of Motivational Interviewing (MI) plus 8 hours of health/nutrition education, or 2) the intensive 9-session MI intervention. In addition to the study interventions, both groups received standard outpatient treatment services at New Leaf. Study participants were assessed weekly during the first 9 weeks of treatment for MA use. More extensive assessments were conducted at treatment entry and 2-, 4-and 6-month follow-ups. Two therapists were "crossed" to treat clients in both conditions. Primary outcome measures included Timeline Follow Back (TLFB) for MA use, MA urinalysis results, and retention in treatment. Secondary outcomes include Addiction Severity Index scales and the TLFB for alcohol and other drugs. A mediation model will build upon MI research proposed by Moyers (2005) and our construct of "supportive confrontation" by testing whether feedback enhanced with warnings about the potential harm of MA use facilitates the therapeutic alliance, and whether this in turn facilitates better outcome. Clients with MA dependence are good candidates for a more intensive dose of MI because of their severe medical and psychosocial problems.
Conditions
- Methamphetamine Dependence
Interventions
- BEHAVIORAL
-
Intensive MI
Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
- BEHAVIORAL
-
Single session MI
Comparator arm that includes 1.5 hours of MI, 8 hours of nutrition classes and outpatient substance abuse treatment
Sponsors & Collaborators
-
Public Health Institute, California
lead OTHER
Principal Investigators
-
Douglas Polcin, Ed.D. · Alcohol Research Group / Public Health Institute
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-02-28
- Primary Completion
- 2012-10-31
- Completion
- 2012-10-31
Countries
- United States
Study Locations
More Related Trials
-
Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study
NCT00653263 ·Status: COMPLETED
-
Methylphenidate to Treat Methamphetamine Dependence
NCT01044238 ·Status: UNKNOWN ·Phase: PHASE2
-
Bupropion for the Treatment of Methamphetamine Dependence - 1
NCT00069251 ·Status: COMPLETED ·Phase: PHASE2
-
Field Study of a Digital Therapeutic Platform to Facilitate Treatment for Methamphetamine-Primary Stimulant Use Disorder
NCT05266716 ·Status: COMPLETED ·Phase: NA
-
A Pilot Trial of Modafinil for Treatment of Methamphetamine Dependence
NCT00538655 ·Status: COMPLETED ·Phase: PHASE2
-
Studying Amphetamine Withdrawal in Humans
NCT01215929 ·Status: COMPLETED ·Phase: PHASE2
-
Effectiveness of Bupropion Combined With Behavioral Therapy for Treating Methamphetamine Dependence - 2
NCT00135785 ·Status: COMPLETED ·Phase: PHASE2
-
Brain Changes in Stimulant Dependent Subjects - 8
NCT00000343 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence
NCT01354470 ·Status: COMPLETED ·Phase: PHASE2
-
Tyrosine for Methamphetamine Dependence - 1
NCT00000322 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Modafinil in Methamphetamine Dependence
NCT00751023 ·Status: COMPLETED ·Phase: PHASE4
-
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence
NCT01011829 ·Status: COMPLETED ·Phase: PHASE2
-
Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0)
NCT01888835 ·Status: COMPLETED ·Phase: PHASE2
-
Citicoline Treatment of Methamphetamine Dependence
NCT00950352 ·Status: COMPLETED ·Phase: PHASE3
-
Modafinil for Methamphetamine Dependence
NCT00859573 ·Status: TERMINATED ·Phase: PHASE2
-
Digital Therapeutics Smartphone Application for Methamphetamine Use Disorder
NCT05550493 ·Status: COMPLETED ·Phase: NA
-
Study of Pomaglumetad and Methamphetamine
NCT03106571 ·Status: TERMINATED ·Phase: PHASE1
-
Topiramate for the Treatment of Methamphetamine Dependence - 1
NCT00345371 ·Status: COMPLETED ·Phase: PHASE2
-
Individualized Neuromodulation for the Core Clinical Features of Drug Addiction
NCT06165198 ·Status: COMPLETED ·Phase: NA
-
Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder
NCT06788587 ·Status: RECRUITING ·Phase: PHASE2
-
Varenicline as a Treatment for Methamphetamine Dependence
NCT01571167 ·Status: COMPLETED ·Phase: PHASE1
-
Methylphenidate Treatment for Cocaine Abuse and ADHD - 1
NCT00136734 ·Status: COMPLETED ·Phase: PHASE1
-
Targeting Drug Memories With Methylphenidate
NCT05978167 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
A Pilot Trial of Dextroamphetamine for Methamphetamine Dependence
NCT00630682 ·Status: COMPLETED ·Phase: PHASE2
-
Methamphetamine Cue-reactivity
NCT07086014 ·Status: RECRUITING